Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 888-897

  Okeley, Nicole M ^a   Miyamoto, Jamie B ^a   Zhang, Xinqun ^a   Sanderson, Russell J ^a   Benjamin, Dennis R ^a   Sievers, Eric L ^a   Senter, Peter D ^a   Alley, Stephen C ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CD30 ANTIGEN; MONOCLONAL ANTIBODY; MONOMETHYLAURISTATIN E; SGN 35; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL KILLING; CONJUGATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; MIXED TUMOR; PRIORITY JOURNAL; RADIOMETRY;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD30; BYSTANDER EFFECT; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; IMMUNOCONJUGATES; OLIGOPEPTIDES;

EID: 76049122850     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2069     Document Type: Article

References (41)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-8.
2. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349-56.
3. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3acute myeloid leukaemia: results of a prospective, pilot,multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138:186-95.
4. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6.
5. Damle NK. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 2004;4:1445-52.
6. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19: 176-82.
7. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69.
8. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
9. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
10. Bartlett N, Forero-Torres A, Rosenblatt J, et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol (Meeting Abstracts) 2009;27:8500.
11. Beeram M, Krop I, Modi S, et al. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). J Clin Oncol (Meeting Abstracts) 2007;25:1042.
12. Krop I, Beeram M, Modi S, et al. A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer [abstract 310]. 30th Annual San Antonio Breast Cancer Symposium; 2007.
13. Younes A, Forero-Torres A, Bartlett NL, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. ASH Annual Meeting Abstracts 2008;112:1006.
14. Younes A, Forero-Torres A, Bartlett N, et al. A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study [abstract PO99bis]. 7th International Symposium on Hodgkin Lymphoma; 2007.
15. Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Kennedy DA, Sievers EL. Robust Antitumor Activity of the Antibody-Drug Conjugate SGN-35 when Administered Every 3 Weeks to Patients with Relaspsed or Refractory CD30 Positive Hematologic Malignancies in a Phase 1 Study [abstract 0503]. European Hematology Association 14th Congress; 2009.
16. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
17. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
18. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
19. Oflazoglu E, Kissler K, Sievers E, Grewal I, Gerber H. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142:69-73.
20. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005;11:843-52.
21. Sutherland MSK, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540-7.
22. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
23. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
24. Schmitz R, Stanelle J, Hansmann ML, Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009;4:151-74.
25. Kasamon YL, Ambinder RF. Immunotherapies for Hodgkin's lymphoma. Crit Rev Oncol Hematol 2008;66:135-44.
26. Sun MM, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005;16:1282-90.
27. Kassis AI, Adelstein SJ. A rapid and reproducible method for the separation of cells from radioactive media. J Nucl Med 1980;21: 88-90.
28. Tu C, Ortega-Cava CF, Chen G, et al. Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res 2008;68:9147-56.
29. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
30. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linkerdrug selection. Cancer Res 2009;69:2358-64.
31. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18:2282-92.
32. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
33. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004;10:7842-51.
34. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32.
35. Jackson D, Gooya J, Mao S, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 2008;68:9367-74.
36. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12: 2591-6.
37. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
38. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66: 3214-21.
39. Fargion S, Carney D, Mulshine J, et al. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 1986;46:2633-8.
40. Grainger JL, von Brunn A, Winkler MM. Transient synthesis of a specific set of proteins during the rapid cleavage phase of sea urchin development. Dev Biol 1986;114:403-15.
41. Jain RK. Tumor physiology and antibody delivery. Front Radiat Ther Oncol 1990;24:32-46.